LYEL — Lyell Immunopharma, Inc.

Is LYEL overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of August 19, 2026

Lyell Immunopharma, Inc. (LYEL) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $15.79. The rating moved from Oversold to Overbought on August 19, 2026.

See all overbought Healthcare stocks →

AI analysis

Lyell Immunopharma is a clinical-stage immunotherapy company with a platform that could generate meaningful upside if early T‑cell programs produce positive readouts or partnerships are announced. Current market themes favor biologics and CRO suppliers, which may provide near-term sentiment support, but the company remains exposed to typical clinical-stage risks—notably trial binary outcomes, cash runway concerns, and potential dilution. Valuation is therefore sensitive to upcoming data and financing developments; expect elevated volatility and scenario-driven moves over the next several weeks.

Key factors

  • Clinical-stage immunotherapy pipeline with differentiated T-cell engineering platform that could address solid tumor indications.
  • Sector tailwinds for biologics, mRNA/oncology readthroughs, and increased demand for CRO/CDMO services supporting commercial upside for partners and suppliers.
  • Recent market environment showing cautious risk-on flows and appetite for growth names, which can temporarily support valuation ahead of catalysts.
  • Partnership and platform optionality that could enable upside through collaborations or licensing if early clinical signals are favorable.
  • Balance-sheet / cash runway uncertainty typical for clinical-stage biotechs makes near-term financing or dilution a material factor for valuation.

Risks

  • Clinical trial failure or weaker-than-expected efficacy/safety data in key programs, which would materially reduce upside.
  • High cash burn and need to raise capital, leading to dilution for existing shareholders if financing occurs at lower prices.
  • Regulatory risk and long, binary approval pathways common to cell- and gene-related immunotherapies.
  • Intense competition from larger oncology-biologics players and emerging cell‑therapy platforms, which could limit market share.
  • Payer/pricing pressures and changing reimbursement dynamics that could affect long-term commercial value.
  • Biotech sentiment volatility and macro-driven repricing (rates, risk appetite) that can amplify share-price moves.
  • Operational execution risk around manufacturing scale-up, CMC challenges, and commercialization readiness.

See today's live rating, score and targets

Members see the live hourly rating for LYEL — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.